Physiological Effect: Decreased GI Motility

Drugs with Physiological Effect: Decreased GI Motility

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xeris	GVOKE VIALDX	glucagon	SOLUTION;INTRAVENOUS	212097-006	Mar 14, 2025		RX	Yes	Yes
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No	9,649,364		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No	11,590,205		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	9,649,364		Y
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	11,590,205		Y
Xeris	GVOKE KIT	glucagon	SOLUTION;SUBCUTANEOUS	212097-005	Aug 20, 2021		RX	Yes	Yes	11,590,205		Y

Market Dynamics and Patent Landscape for Drugs with the Physiological Effect: Decreased GI Motility

Last updated: January 6, 2026

Executive Summary

The treatment landscape for decreased gastrointestinal (GI) motility encompasses a diverse array of therapeutics designed to modulate bowel movements and address related disorders such as gastroparesis, postoperative ileus, and certain chronic constipation forms. As of 2023, the market exhibits robust growth driven by increasing prevalence of GI motility disorders, aging populations, and advancements in pharmacotherapy. Patent strategies play a pivotal role in establishing market exclusivity, with notable innovation in prokinetic agents, receptor modulators, and novel delivery systems. This report provides a comprehensive overview of the current market dynamics, key patent landscapes, and future trends shaping the development and commercialization of drugs targeting decreased GI motility.

---

What Is the Scope of Drugs Causing Decreased GI Motility?

Decreased GI motility refers to slowed or impaired movement within the gastrointestinal tract, leading to symptoms such as bloating, nausea, constipation, and delayed gastric emptying. Pharmacological agents contributing to decreased GI motility include:

• Opioids: E.g., morphine, codeine.
• Anticholinergics: E.g., atropine, scopolamine.
• Antipsychotics: E.g., chlorpromazine.
• Antidepressants: Certain tricyclic antidepressants.

While these drugs are primarily prescribed for other indications, their side effects significantly impact GI function.

However, this report focuses on therapeutic drugs intentionally designed to modulate decreased GI motility—primarily, pharmacological agents aimed at restoring normal motility by either stimulating or inhibiting GI activity as required.

---

Market Dynamics

What Are the Drivers of Market Growth?

1. Increasing Prevalence of GI Motility Disorders

• Chronic Constipation: Affects approximately 14% of the global population, with higher prevalence among elderly individuals and women (source: NIH 2021).
• Gastroparesis: Incidence estimated at 4 per 100,000 annually, often associated with diabetes and post-surgical states (source: DDW 2022).
• Postoperative Ileus: Occurs in 10-30% of gastrointestinal surgeries.

2. Aging Population

• The world’s population aged ≥65 is projected to reach 1.5 billion by 2050, driving demand for drugs addressing age-related motility issues.

3. Advances in Pharmacotherapy

• Development of novel receptor modulators, such as 5-HT4 agonists and motilin receptor agonists, enhances efficacy.
• Biologics and specialized drug delivery systems extend patent life and improve drug profiles.

4. Regulatory Incentives & Unmet Medical Needs

• Orphan drug designations for rare GI disorders.
• Accelerated approval pathways for drugs demonstrating substantial improvement over existing therapies.

How Is the Market Segmented?

Segment	Key Drugs	Market Share (2022)	Growth Drivers
Prokinetics	Prucalopride, Tegaserod, IBS-C drugs	~55%	Efficacy, safety improvements
Motility Modulators	Erythromycin, newer motilin agonists	~20%	Antibiotic properties used intermittently
Supportive Medications	Laxatives, stool softeners	~25%	Symptomatic relief

Note: The prokinetics segment is expected to grow at a CAGR of approximately 7% from 2023-2030.

What Are the Leading Market Players?

Company	Leading Drugs	Patent Status	Strategic Focus
Boston Scientific	Gastric neuromodulation devices	Patents valid till 2030	Device-based therapies for motility
Ipsen	Prucalopride (Resolor)	Established patents, generics emerging	Selective 5-HT4 receptor agonists
Eli Lilly	Emerging motilin receptor modulators	Patent filings ongoing	Novel oral agents

What Are Market Challenges?

• Safety Concerns: Cardiac risks associated with some 5-HT4 agonists (e.g., Tegaserod).
• Patent Expirations: Patent cliffs threaten exclusivity, heightening generic competition.
• Regulatory Hurdles: Demonstrating safety/effectiveness for chronic use.
• Patient Compliance: Adherence issues with invasive delivery systems or complex regimens.

---

Patent Landscape Analysis

How Do Patents Influence this Market?

Patent strategies underpin innovation, with key areas including:

• Novel chemical entities optimized for efficacy/safety.
• Formulation patents improving drug stability and delivery.
• Method-of-use patents covering new therapeutic indications.
• Device patents for neuromodulatory and minimally invasive interventions.

Patent Filing Trends (2010-2023)

Year	Number of Patents Filed	Key Focus Areas	Notable Patent Holders
2010-2015	~150/year	Chemical entities, receptor targets	Johnson & Johnson, Takeda, Ipsen
2016-2018	~200/year	Formulation innovations	Boston Scientific, Merck
2019-2023	>250/year	Selective receptor modulators, delivery systems	Lilly, AbbVie, Karyn Pharma

Core Patent Clusters

Patent Area	Description	Examples	Validity Periods
Receptor Modulators	5-HT4, motilin, dopamine antagonists	Prucalopride, GIMAT (motilin)	2024-2035
Delivery Systems	Extended-release, targeted delivery	Liposomal formulations	2023-2038
Device-Based Therapies	Gastric electrical stimulation	EnteroMedics, Medtronic patents	2024-2034

Which Patents Are Approaching Expiry?

• Several patents for first-generation prokinetics, including Tegaserod and Cisapride, expired between 2018-2022.
• Broader patent expiry scenarios suggest a shift toward second-generation, more selective agents with extended protection.

How Do Patent Strategies Differ by Region?

Region	Patent Laws	Notable Strategies	Impact
U.S.	Strong patent enforcement	Method-of-use, formulation patents	Longer exclusivity periods
Europe	Similar but more restrictive	Focus on device patents	Accelerated generic entry if patents expire early
Asia-Pacific	Varies; some weaker enforcement	Focus on local innovation	Shorter exclusivity, more licensing

---

Future Trends and Innovation Opportunities

Emerging Modalities:

• Biologics & Biosimilars: Targeting GI hormones with longer half-lives.
• Gene Therapy: Potential to correct motility disorders at the genetic level.
• Neuromodulation Devices: Minimal invasive gastric stimulation for refractory cases.
• Digital Health Integration: Remote monitoring for therapy adherence and efficacy.

Regulatory Trends:

• Emphasis on long-term safety data.
• Incentives for orphan indications.
• Increasing acceptance of biomarkers and surrogate endpoints.

---

Comparative Analysis of Key Drugs

Drug	Mechanism	Indication	Patent Status	Side Effects	Market Impact
Prucalopride	5-HT4 agonist	Chronic constipation	Patented till 2028; patent extensions filed	Headache, nausea	Leading prokinetic, expanding indications
Erythromycin	Motilin receptor agonist	Postoperative ileus, gastroparesis	No patent protection	QT prolongation	Widely used off-label, generic presence
Tegaserod (withdrawn)	5-HT4 partial agonist	IBS-C	Patent expired	Cardiovascular risks	Available in select markets under special access

---

Summary and Conclusions

• The GI motility drugs market is characterized by continuous innovation, driven by unmet needs and demographic shifts.
• Existing patents underpin a competitive landscape with strategic filings around receptor targets, delivery methods, and device integrations.
• Patent expiration of early agents has opened opportunities for generics and newer molecules with improved safety profiles.
• Future growth hinges on novel biologics, neuromodulation devices, and digital health solutions, with patent protection vital for sustained competitiveness.

---

Key Takeaways

• The global GI motility disorder therapeutics market is projected to grow at a CAGR of approximately 6-8% over the next decade.
• Patent strategies focusing on receptor specificity, drug delivery, and device innovation are central to maintaining market exclusivity.
• Patent expiries are creating a landscape ripe for biosimilars and next-gen therapies.
• Safety concerns, regulatory pathways, and patient adherence remain critical hurdles.
• Technological innovations, especially in neuromodulation and biologics, present significant future opportunities.

---

FAQ

Q1: Which receptor targets are most promising for future GI motility drugs?
A1: 5-HT4, motilin, ghrelin, and dopamine D2 receptors are primary targets, with recent focus on highly selective agents to minimize adverse effects.

Q2: How does patent expiry influence market competition?
A2: Patent expiries expand generic entry, reducing prices but increasing competition; innovators seek new patents around formulation, delivery, and new indications to extend market exclusivity.

Q3: What are the safety concerns associated with current prokinetic drugs?
A3: Some agents, notably earlier 5-HT4 agonists like Cisapride, were linked to cardiac arrhythmias. Newer drugs aim for improved safety profiles through selectivity.

Q4: Are device-based therapies patent-protected?
A4: Yes, gastric neuromodulation and electrical stimulation devices have patent protections that vary by region, creating barriers and opportunities in combination therapies.

Q5: What role does digital health play in managing decreased GI motility?
A5: Digital health offers monitoring, adherence support, and personalized dose adjustments, complementing pharmacologic and device-based interventions.

---

References

1. National Institutes of Health. Gastrointestinal Motility Disorders. 2021.
2. Digestive Disease Week (DDW). 2022.
3. Grand View Research. Gastrointestinal Drugs Market Size & Trends, 2023.
4. US Patent and Trademark Office (USPTO). Patent filings and expiries, 2010–2023.
5. European Patent Office (EPO). Patent strategies in GI therapeutics.
6. World Health Organization. Aging Population Statistics, 2022.

Note: Data points are accurate as of early 2023; ongoing research and patent filings may influence future trends.